Explanipedia

Elebsiran and PEG-IFNα for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial Open

Grace Lai‐Hung Wong, Man‐Fung Yuen, Bingliang Lin, Mark W. Douglas, Peng Hu , et al. · 2025

Functional cure is a goal for the treatment of chronic hepatitis B virus (HBV) infection; however, it is infrequently achieved with currently approved treatments. Here we provide a randomized evaluation of the small interfering RNA elebsir…

Enhancing antifungal stewardship: The educational and healthcare benefits of involving pharmacy students in audits Open

Daniel Nguyen, Gabrielle Louise Langron Chau, Savannah Reali, Matthew Watts, Mark W. Douglas , et al. · 2025

Antifungal stewardship is important for promoting quality care and tackling the emergence of drug resistance. Evaluation of the quantity and appropriateness of common antifungal prescriptions like fluconazole is essential in the developmen…

Twelfth scientific biennial meeting of the Australasian Virology Society: AVS12 2024 Open

Ebony A. Monson, Robson Kriiger Loterio, Justin A. Roby, Anurag Adhikari, Rowena A. Bull , et al. · 2025

The Australasian Virology Society (AVS) holds premier biennial virology meetings that foster multidisciplinary research and collaboration and promote equity and inclusion of early-career researchers. The 12th AVS meeting (AVS12), convened …

Novel digital droplet inverse PCR assay shows that natural clearance of hepatitis B infection is associated with fewer viral integrations Open

Dong Li, Vikki Ho, Chiao‐Fang Teng, Hung‐Wen Tsai, Yuanyuan Liu , et al. · 2025

Hepatitis B virus (HBV) DNA integration into the host cell genome is reportedly a major cause of liver cancer, and a source of hepatitis B surface antigen (HBsAg). High HBsAg levels can alter immune responses which therefore contributes to…

<i>Listeria monocytogenes</i> Endophthalmitis—Good Outcome With Rapid Diagnosis Using MALDI‐TOF and Treatment With Benzylpenicillin and Trimethoprim–Sulfamethoxazole Open

Thomas Ledger, Martin Plymoth, Mark W. Douglas · 2025

Purpose: Describe a case of rapidly diagnosed Listeria monocytogenes endophthalmitis, with a clearly established route of endogenous seeding, treated with dual antibiotics, with outcomes better than many reported. Observations: A 79‐year‐o…

Bivalent Omicron BA.1 vaccine booster increases memory B cell breadth and neutralising antibodies against emerging SARS-CoV-2 variants Open

Lok Bahadur Shrestha, Katie Tungatt, Anupriya Aggarwal, Aija Stubis, Nicole Fewings , et al. · 2024

Telehealth Use and Legal Considerations in Drug Health Services During Pandemics: Systematic Scoping Review Open

Meryem Jefferies, Robert Graham, Marguerite Tracy, N. Scott Reading, Mohammed Eslam , et al. · 2024

Background The COVID-19 pandemic impacted patients with substance use disorder (SUD) more than the general population and resulted in substantially increased emergency department admissions. Routine care of patients attending drug health s…

BCG vaccination of healthcare workers for protection against COVID-19: 12-month outcomes from an international randomised controlled trial Open

Nicole L. Messina, Laure F. Pittet, Ellie McDonald, Cecilia Moore, Simone Barry , et al. · 2024

Oral Microbiome and Treatment Resistance Status in Schizophrenia: A Cross-sectional Study Open

Anoop Sankaranarayanan, Preethi Ramanathan, Martha Zakrzewski, Deepali Vasani, Ramanathan Ganapathy , et al. · 2024

Hepatitis B Virus and Hepatitis C Virus Affect Mitochondrial Function Through Different Metabolic Pathways, Explaining Virus-Specific Clinical Features of Chronic Hepatitis Open

Sakthi Priya Selvamani, Anis A. Khan, Enoch Tay, Matthew Garvey, Harout Ajoyan , et al. · 2024

Background Hepatitis C virus (HCV) and hepatitis B virus (HBV) cause chronic hepatitis with important clinical differences. HCV causes hepatic steatosis and insulin resistance, while HBV confers increased risk of liver cancer. We hypothesi…

Hepatitis C Virus Antiviral Drug Resistance and Salvage Therapy Outcomes Across Australia Open

Dao Sen Wang, Amy Phu, Kristen McKee, Simone I. Strasser, Sinead Sheils , et al. · 2024

Background Hepatitis C virus (HCV) infection can now be cured with well-tolerated direct-acting antiviral (DAA) therapy. However, a potential barrier to HCV elimination is the emergence of resistance-associated substitutions (RASs) that re…

Special Issue “Hepatitis B Virus: New Breakthroughs to Conquer an Ancient Disease” Open

Thomas Tu, Mark W. Douglas · 2023

Chronic hepatitis B affects >300 million people worldwide and is a major cause of liver disease, causing ~800,000 deaths each year [...]

Bacillus Calmette-Guérin vaccination for protection against recurrent herpes labialis: a nested randomised controlled trial Open

Laure F. Pittet, Cecilia Moore, Ellie McDonald, Simone Barry, Marc J. M. Bonten , et al. · 2023

Polo-like kinase-1 mediates hepatitis C virus-induced cell migration, a drug target for liver cancer Open

Korri Elvanita El-Khobar, Enoch Tay, Eve Diefenbach, Brian Gloss, Jacob George , et al. · 2023

Polo-like kinase 1 (PLK1) is a regulator of cell mitosis and cytoskeletal dynamics. PLK1 overexpression in liver cancer is associated with tumour progression, metastasis, and vascular invasion. Hepatitis C virus (HCV) NS5A protein stimulat…

Targeting liver metabolism: a pathway to cure hepatitis B virus? Open

Harout Ajoyan, Mark W. Douglas, Thomas Tu · 2023

PEMT Mediates Hepatitis C Virus-Induced Steatosis, Explains Genotype-Specific Phenotypes and Supports Virus Replication Open

Mosleh Mohammad Abomughaid, Enoch Tay, Russell Pickford, Chandra S. Malladi, Scott Read , et al. · 2023

The hepatitis C virus (HCV) relies on cellular lipid pathways for virus replication and also induces liver steatosis, but the mechanisms involved are not clear. We performed a quantitative lipidomics analysis of virus-infected cells by com…

Inhibition of cellular factor TM6SF2 suppresses secretion pathways of Hepatitis B, Hepatitis C and Hepatitis D viruses Open

Thomas Tu, Harout Ajoyan, Rifqiyah nur Umami, Vaishnavi Veeraraghavan, Mustafa A. Najim , et al. · 2023

Introduction Chronic viral hepatitis, a leading cause of global deaths, is caused by three enveloped viruses from distinct families: hepatitis B virus, hepatitis C virus, and hepatitis D virus (HBV, HCV, and HDV). Despite having different …

Nodular Syphilis Seen in an HIV-Positive Man: A Case Study Open

Andrew Burchak, Robert Rivera, Mark W. Douglas · 2023

Syphilis is becoming an increasingly concerning sexually transmitted infection in the primary care setting with a precipitous rise in cases in the USA over the past decade according to the CDC surveillance data. This rise in cases is parti…

Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level Open

Anouschka Akerman, Vanessa Milogiannakis, Tyra Jean, Camille Esneau, Mariana Ruiz Silva , et al. · 2023

This work was primarily supported by Australian Medical Foundation research grants MRF2005760 (SGT, GM & WDR), Medical Research Future Fund Antiviral Development Call grant (WDR), the New South Wales Health COVID-19 Research Grants Round 2…

Telehealth Use and Legal Considerations in Drug Health Services During Pandemics: Systematic Scoping Review (Preprint) Open

Meryem Jefferies, Robert Graham, Marguerite Tracy, N. Scott Reading, Mohammed Eslam , et al. · 2023

BACKGROUND The COVID-19 pandemic impacted patients with substance use disorder (SUD) more than the general population and resulted in substantially increased emergency department admissions. Routine care of patients attending drug health …

Issue Information Open

Paul Bridgman, Sudhesh Kumar, Jonathan Brett, Sydney Bonomo, Christopher Pokorny , et al. · 2023

Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sublineages in the face of maturing antibody breadth at the population level Open

Anouschka Akerman, Vanessa Milogiannakis, Tyra Jean, Camille Esneau, Mariana Ruiz Silva , et al. · 2022

The Omicron era of the COVID-19 pandemic commenced at the beginning of 2022 and whilst it started with primarily BA.1, it was latter dominated by BA.2 and related sub-lineages. Over the course of 2022, we monitored the potency and breadth …

Mitosis of hepatitis B virus-infected cells in vitro results in uninfected daughter cells Open

Thomas Tu, Benno Zehnder, Jochen M. Wettengel, Henrik Zhang, Sally Coulter , et al. · 2022

COVID-19 Impact on Australian Patients with Substance Use Disorders: Emergency Department Admissions in Western Sydney before Vaccine Roll Out Open

Meryem Jefferies, Harunor Rashid, R. Graham, Scott Read, Gouri Rani Banik , et al. · 2022

Background: In this study, we determined the impact of the COVID-19 pandemic on Western Sydney patients with substance use disorders (SUD) by comparing emergency department (ED) admission rates before and after the onset of the COVID-19 pa…

Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals Open

A Howe, Chaturaka Rodrigo, Evan B. Cunningham, Mark W. Douglas, Julia Dietz , et al. · 2022

Mitosis of Hepatitis B virus-infected cells results in uninfected daughter cells Open

Thomas Tu, Benno Zehnder, Jochen M. Wettengel, Henrik Zhang, Sally Coulter , et al. · 2022

Chronic hepatitis B is a major cause of liver failure and liver cancer, resulting in 600,000 annual deaths globally. Infection chronicity (and resultant liver disease) is determined by intrahepatic persistence of the viral covalently close…

Emergence and Antibody Evasion of BQ and BA.2.75 SARS-CoV-2 Sublineages in the Face of Maturing Antibody Breadth at the Population Level Open

Anouschka Akerman, Vanessa Milogiannakis, Tyra Jean, Camille Esneu, Mariana Ruiz Silva , et al. · 2022

SHARED: An International Collaboration to Unravel Hepatitis C Resistance Open

A Howe, Francesca Ceccherini‐Silberstein, Julia Dietz, Stephanie Popping, Jason Grebely , et al. · 2021

The advent of direct-acting antivirals (DAAs) has transformed the treatment landscape of hepatitis C [...]

Viral Biomarkers for Hepatitis B Virus-Related Hepatocellular Carcinoma Occurrence and Recurrence Open

Yuanyuan Liu, Vaishnavi Veeraraghavan, Monica Pinkerton, Jianjun Fu, Mark W. Douglas , et al. · 2021

Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and the fourth leading cause of cancer-related death. The most common risk factor for developing HCC is chronic infection with hepatitis B virus (HBV). Early stages o…

Special Issue “Hepatitis B Virus Infection: From Diagnostics to Treatments” Open

Thomas Tu, Mark W. Douglas · 2020

In this Special Issue, we have brought together a broad range of studies on hepatitis B virus (HBV) covering diagnosis, pathogenesis, monitoring, and treatment [...]

Mark W. Douglas YOU? Author Swipe